| Document |
Document Title |
|
WO/2016/189287A1 |
The present disclosure relates to new compounds and their use as fluorescent labels. The compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications. The labels are advantageous due to their long S...
|
|
WO/2016/189055A1 |
The present application relates to novel nucleoside derivatives of formula (I) as claimed in claim 1, pharmaceutical compositions comprising the compounds, processes of preparation thereof, and methods of use thereof for treating cancer.
|
|
WO/2016/184361A1 |
Disclosed are a compound represented by general formula (I), and pharmaceutically acceptable salt thereof, wherein A is O or C=CH2; B is a nucleoside base; Z is a connecting bond or CHR4; when W is a connecting bond or C(O), R is CH(R')C...
|
|
WO/2016/182984A1 |
The present disclosure provides methods of sequencing polynucleotides and compounds, compositions useful for sequencing of polynucleotides. The chemical compounds include nucleotides and their analogs which possess a sugar moiety compris...
|
|
WO/2016/177300A1 |
Disclosed are a compound of formula I, and preparation method and intermediate thereof; the use of the compound of formula I in preparing a drug for treating viral infections; the use of the compound of formula I in preparing sofosbuvir ...
|
|
WO/2016/174081A1 |
The present invention relates to novel pro-drugs of L-2'-deoxythreose nucleoside phosphonates, such as phosphoramidate, phosphorodiamidate and phospho-diester prodrugs. The invention also relates to a process for preparing these novel pr...
|
|
WO/2016/176193A1 |
Disclosed herein is a method to specifically remove alloreactive T cells. In one example, the method includes culturing donor cells comprising donor T cells with recipient antigen presenting cells (APCs) to form a mixture of cells under ...
|
|
WO/2016/168911A1 |
The present invention is directed to purine nucleoside analogs of the general formula (I) or salts and pharmaceutical compositions comprising such compounds and salts, which are useful as anti-protozoan agents. The invention is also dire...
|
|
WO/2016/168735A1 |
In various embodiments, a cell culture medium, or a nucleoside cocktail transmission (NCT) medium for the culture of stem cells with improved genetic stability, cellular function and regeneration ability is provided. Illustrative culture...
|
|
WO/2016/168750A1 |
The present invention provides nucleic acid probes comprising two quenchers of excited state energy, and methods of their use.
|
|
WO/2016/160646A1 |
The present invention is directed to processs for making Compounds of Formula (II): (II), and salts thereof, wherein B, X, R2, R3, R4 R7, R8 and R9 are defined herein.
|
|
WO/2016/159836A1 |
The invention relates to the field of organic chemistry and medicine, and more particularly to synthetic substances of the pyrimidine series, namely 2-chloro-5-phenyl-5H-pyrimido[5',4':5,6]pyrano[2,3-d]pyrimid
ine-4-ol derivatives, havin...
|
|
WO/2016/160524A1 |
The invention provides a process for the preparation of nicotinamide mononucleotide having formula (I): The method involves the protection of nicotinamide riboside by ketalization, followed by phosphorylation and then deprotection to pro...
|
|
WO/2016/159374A1 |
The present invention provides a method for producing glycoside compounds represented by general formula (I) or salts thereof, said method comprising: a step (step 0) in which a thioether compound represented by general formula (103) and...
|
|
WO/2016/156512A1 |
A process for preparing a solid crystalline form of sofosbuvir of formula (I) having an X-ray powder diffraction pattern comprising no reflection at 2-theta angles in the range of from 2.0 to 7.8 0 and preferably comprising reflections a...
|
|
WO/2016/155593A1 |
The present invention relates to a novel compound of 4'-thionucleoside, a preparation method therefor, a pharmaceutical composition comprising the same and an application thereof. Specifically, the present invention relates to a phospham...
|
|
WO/2016/161086A1 |
The invention provides compositions and methods for treating glycogen storage diseases or conditions with a buildup of glycogen. Cyclic AMP elevator compositions are shown to reduce glycogen storage in affected cells and therefore can be...
|
|
WO/2016/154013A1 |
HAT-Pi chemotherapy arrests uncontrolled replication and metastatic migration of neoplastic cells by inhibiting enzymatic activity of poly (ADP-ribose) polymerase 1 (PARP 1) through administration of one or more halogenated analogs of th...
|
|
WO/2016/151542A1 |
The present invention relates to an industrially applicable process for the preparation of phosphoramidates useful for the treatment of viral infections, such as sofosbuvir, and to intermediates useful for the preparation thereof. Formul...
|
|
WO/2016/147185A1 |
Novel adenosine 5'-thiophosphate derivatives, represented by Formulae (I) or (I*), and salts thereof, represented by Formulae (Ia) and (I*a), as defined in the specification, and uses thereof as antioxidants and/or P2Y1-R agonists, and/o...
|
|
WO/2016/146808A1 |
The invention relates to a new synthethic process for obtaining compounds of formula (I) from compounds of formula (II) by means of cytidine deaminase enzymes.
|
|
WO/2016/149395A1 |
Derivatives of nicotinic acid riboside (NAR), nicotinamide riboside (NR), and reduced NAR and NR, including 1-(2', 3', 5'-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinic acid (4a), and compositions containing the same and/or reduced...
|
|
WO/2016/145142A1 |
This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or t...
|
|
WO/2016/144918A1 |
A compound of the structure (A), or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.
|
|
WO/2016/144660A1 |
Provided are crystalline forms of nicotinamide riboside, including a Form II of nicotinamide riboside chloride: nicotinamide riboside chloride. Also disclosed are pharmaceutical compositions comprising the crystalline Form II of nicotina...
|
|
WO/2016/140616A1 |
Compound 1 with the formula I is an HCV antiviral protide, which is surprisingly soluble in ethanol, thereby facilitating the preparation of pharmaceutical formulations, such as adsorbed mesoporous carriers or SEDDS of Pouton Types III o...
|
|
WO/2016/140615A1 |
Use of a compound represented by formula (1A), or a pharmaceutically acceptable salt thereof, in the therapy of HCV in a mammal or human, wherein the compound of formula 1A is administered in combination with a further HCV antiviral sele...
|
|
WO/2016/138035A1 |
Methods of conjugating oligonucleotides are provided. The methods may include: activating a terminal of first oligonucleotide using a squarate reagent to produce an activated first oligonucleotide; and binding the first oligonucleotide a...
|
|
WO/2016/135582A1 |
Compounds of the general Formula (I): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
|
|
WO/2016/138026A1 |
Compositions and methods in the field of medicine and chemistry are disclosed. Some of the disclosed embodiments are directed to nucleotide compounds, medicinal compositions, as well as processes for their preparation and methods of thei...
|
|
WO/2016/134056A1 |
The present invention features compounds of e.g. formula (I) effective in inhibiting Hepatitis C virus ("HCV") polymerase. The invention also features compositions comprising such compounds and methods of using such compounds to treat HC...
|
|
WO/2016/134054A1 |
The present invention features compounds of e.g. formula (I) effective in inhibiting Hepatitis C virus ("HCV") polymerase. The invention also features compositions comprising such compounds and methods of using such compounds to treat HC...
|
|
WO/2016/134053A1 |
The present invention features compounds of e.g. formula I effective in inhibiting Hepatitis C virus ("HCV") polymerase. The invention also features compositions comprising such compounds and methods of using such compounds to treat HCV ...
|
|
WO/2016/134057A1 |
The present invention features compounds of e.g. formula (I) effective in inhibiting Hepatitis C virus ("HCV") polymerase. The invention also features compositions comprising such compounds and methods of using such compounds to treat HC...
|
|
WO/2016/134051A1 |
The present invention features compounds of e.g. formula I effective in inhibiting Hepatitis C virus ("HCV") polymerase. The invention also features compositions comprising such compounds and methods of using such compounds to treat HCV ...
|
|
WO/2016/130691A1 |
Disclosed herein is a method for treating heart failure in a subject in need thereof. The method includes administering a therapeutically effective amount of nicotinamide riboside to the subject. The heart failure may be associated with ...
|
|
WO/2016/126734A1 |
Novel processes for making the N-pyrrazole substituted 2-adenosine derivative regadenoson and a novel polymorph thereof. The novel polymorph of regadenoson designated form H and drug substances and pharmaceutical compositions including t...
|
|
WO/2016/120403A1 |
The present invention relates to a compound of the general formula (1). wherein the pyranose ring is a-D-galactopyranose, A is selected from The compound of formula (1) is suitable for use in a method for treating a disorder relating to ...
|
|
WO/2016/123397A2 |
The present disclosure provides nucleoside analogs of Formula (I) or (II). The nucleoside analogs may show multiple tautomerism and may increase the mutation of an RNA and/or DNA (be mutagenic) of a virus or cancer cell. The multiple tau...
|
|
WO/2016/120305A1 |
A compound of formula (I) Or a pharmaceutically acceptable salt and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of sai...
|
|
WO/2016/112746A1 |
Disclosed in the present invention is a method for preparing ribofuranose phosphate derivatives, and the preparation steps thereof comprises: coupling starting materials of isopropyl L-alanine hydrochloride, phenol dichlorophosphate and ...
|
|
WO/2016/113335A1 |
The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal...
|
|
WO/2016/110761A1 |
An efficient and simple process is provided for producing 1-β-D-arabinofuranosylcytosine or cytarabine wherein cytidine hydrochloride is converted to the corresponding 2,2'- anhydro-1-β-D-arabinofuranosylcytosine hydrochloride by react...
|
|
WO/2016/107289A1 |
The present invention relates to a method for preparing Sofosbuvir crystal form-6. The method is simple in operation, stable in process condition, good in reproducibility, high in yield rate and high in purity, viscous gel-type products ...
|
|
WO/2016/105449A1 |
This disclosure provides compounds and compositions for use as analgesics and for the treatment of one or more conditions selected from: pain; psychic pain; psychological pain; psychiatric pain; depression; allodynia; fibromyalgia; fibro...
|
|
WO/2016/101782A1 |
An oxidized β-nicotinamide adenine dinucleotide phosphate and a purification method therefor, specifically comprising the following steps: a. using membrane concentration equipment to perform microfiltration and then nanofiltration on a...
|
|
WO/2016/106050A1 |
This disclosure relates to N4-hydroxycytidine derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment and prophylaxis of viral infections.
|
|
WO/2016/101412A1 |
Disclosed are a crystallization water-free calcium dibutyryladenosine cyclophosphate crystal form, and a preparation method and a use thereof. In an X-ray powder diffraction pattern using Cu-Kα as a source of radiation, the crystallizat...
|
|
WO/2016/100569A1 |
Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus infection with one or more nucleosides, nucleotides and nucl...
|
|
WO/2016/097173A1 |
A process for preparing a crystalline form of sofosbuvir having an X-ray powder diffraction pattern comprising no reflection at 2-theta angles in the range of from 2.0 to 7.8°, wherein polyethylene glycol is used as additive for solvent...
|
